PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Piflufolastat→

Piflufolastat PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1423758-00-2
Molecular formula
C18H23FN4O8
Molecular weight
442.4 g/mol
Drug class
Diagnostic radiopharmaceuticalPSMA-targeted fluorine-18 PET imaging agent
Mechanism of action
A urea-based ligand binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. The fluorine-18 positron-emitting radionuclide enables PET visualisation of PSMA-expressing lesions.
Indications / reported uses
  • PET imaging of PSMA-positive lesions in men with prostate cancer when metastatic disease is suspected in candidates for initial definitive therapy or recurrence is suspected due to elevated PSA.

Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a00e5cbc-4fd5-4280-82ec-cd3498df4553 · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-piflufolastat

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Piflufolastat PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Piflufolastat Permitted Daily Exposure (PDE) report (the Piflufolastat PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Piflufolastat Occupational Exposure Limit (OEL) report (the Piflufolastat OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.